Agenus Inc. (AGEN)
$
3.39
-0.05 (-1.47%)
Key metrics
Financial statements
Free cash flow per share
-4.4989
Market cap
130.2 Million
Price to sales ratio
1.1399
Debt to equity
-1.2353
Current ratio
0.4125
Income quality
0.6816
Average inventory
0
ROE
-0.0004
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Agenus Inc., a clinical-stage immuno-oncology company operating in the United States and internationally, is focused on discovering and developing innovative immuno-oncology products. The company's operating income ratio is -0.18 indicating the company's operational profitability margin. Additionally, the gross profit ratio is 0.90 reflecting the efficiency of the company's production and sales operations. Agenus Inc. leverages its Retrocyte Display, an advanced antibody expression platform, for identifying fully human and humanized monoclonal antibodies. The organization also develops various vaccine programs, including the Prophage vaccine candidate and QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. Its product pipeline features several promising candidates, such as Balstilimab, an anti-PD-1 antagonist that has completed a Phase II clinical trial for second line cervical cancer, AGEN1181, an anti-CTLA-4 monospecific antibody currently in Phase 1/2 clinical trial, and AGEN2373, an anti-CD137 monospecific antibody in Phase 1 clinical trial. Other notable developments include AGEN1423, a tumor microenvironment conditioning anti-CD73/TGFß TRAP bi-functional antibody that has finished its Phase 1 clinical trial, and AGEN1777, an anti-TIGIT bispecific antibody. Furthermore, AGEN1327 is a human monoclonal antibody, while INCAGN1876, INCAGN1949, INCAGN2390, and INCAGN2385 are specialized anti-GITR, anti-OX40, anti-TIM-3, and anti-LAG-3 monoclonal antibodies, respectively. The company also has ARDS-targeting AGENT 797 in Phase 1 clinical trials, and AGEN1884, a first-generation anti-CTLA-4 antibody. Agenus collaborates with Incyte Corporation, Merck Sharpe & Dohme, Recepta Biopharma SA, and Gilead Sciences, Inc. Founded in 1994 and headquartered in Lexington, Massachusetts, Agenus Inc. was formerly known as Antigenics Inc. and rebranded in January 2011. The company reported depreciation and amortization expenses of $9,999,000.00 reflecting the wear and tear of its assets. The EBITDA is -$10,557,000.00 a key indicator of the company's operational profitability. The financial data pertains to the fiscal year 2025. As a small-cap player with a market capitalization of $130,170,417.00 Agenus controls a pivotal role in the Biotechnology industry, making significant contributions to the overall market landscape. The stock is affordable at $4.38 making it suitable for budget-conscious investors. However, the stock has a low average trading volume of 649,286.00 indicating lower market activity. The company belongs to the Healthcare sector, driving innovation and growth within the evolving landscape of immuno-oncology.
Is Agenus Inc. (AGEN) a good investment?
Investing in Agenus Inc. (AGEN) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C-, with a Bearish outlook. Always conduct your own research before investing.
What is Agenus Inc. (AGEN)'s stock forecast?
Analysts predict Agenus Inc. stock to fluctuate between $1.38 (low) and $7.34 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Agenus Inc.'s market capitalization?
As of 2026-03-27, Agenus Inc.'s market cap is $130,170,417, based on 38,398,353 outstanding shares.
How does Agenus Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Agenus Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Agenus Inc. (AGEN) stock?
To buy Agenus Inc. (AGEN) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for AGEN. Place an order (Market, Limit, etc.).
What is the best time to invest in Agenus Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
Has Agenus Inc. stock ever split?
Agenus Inc.'s last stock split was 1:20 on 2024-04-12.
How did Agenus Inc. perform in the last earnings report?
Revenue: $114,196,000 | EPS: -$0.00 | Growth: -99.97%.
Where can I find Agenus Inc.'s investor relations reports?
Visit https://www.agenusbio.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Agenus Inc.?
You can explore historical data from here
What is the all-time high and low for Agenus Inc. stock?
All-time high: $135.80 (2021-08-30) | All-time low: $1.38 (2025-04-07).
What are the key trends affecting Agenus Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
businesswire.com
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #BAL--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in immuno-oncology, today announced it will host its March Stakeholder Webcast focused on continued progress of its botensilimab and balstilimab (BOT+BAL) immunotherapy program and will provide an update on the Company's patient access programs, development across tumor types, and key priorities for 2026. The session will be moderated by Garo H. Armen, PhD, Founder, Chairman, and Chief Executive Officer of Agenus.
businesswire.com
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #AACR26--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced that preliminary results from an investigator-sponsored study evaluating botensilimab (BOT) in combination with balstilimab (BAL) in first-line microsatellite stable colorectal cancer (MSS CRC) will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place April 18–23 in San Diego, CA. The BBoPCO study (Botensilimab and Balstilimab Optimization.
zacks.com
Agenus (AGEN) came out with quarterly earnings of $0.56 per share, beating the Zacks Consensus Estimate of a loss of $1.27 per share. This compares to a loss of $2.04 per share a year ago.
businesswire.com
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #BOT--Agenus Inc. (Nasdaq: AGEN) today reported financial results for the fourth quarter and full year ended December 31, 2025, highlighting progress for the botensilimab (BOT) plus balstilimab (BAL) immunotherapy program across patient access, clinical execution, and commercial readiness. BOT+BAL is a next-generation CTLA-4/PD-1 immunotherapy combination which activates both innate and adaptive immunity and has demonstrated immunotherapy benefit in tumors historica.
businesswire.com
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #AGEN--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that it has triggered the first $20 million contingent payment under its previously disclosed strategic collaboration with Zydus Lifesciences Ltd. The payment was triggered by contracted work orders for critical chemistry, manufacturing and controls (CMC) and production activities related to botensilimab (BOT) and balstilimab (BAL). These activities will allow Zydus to perform.
businesswire.com
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #Agenus--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in immuno-oncology, today announced that the Company will release its fourth quarter and year-end 2025 financial results before the market opens on Monday, March 16, 2026. Agenus will host a stakeholder briefing webcast in late March to spotlight key strategic plans, data milestones and provide an update on the global botensilimab (BOT) and balstilimab (BAL) development program. About Agenus Agenus is a leading i.
businesswire.com
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #AACRIO26--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced new translational and clinical biomarker data from its Phase 1b C-800-01 trial (NCT03860272) evaluating botensilimab (BOT), an Fc-enhanced anti–CTLA-4 antibody, in combination with balstilimab (BAL), an anti–PD-1 antibody. The data were presented today at the American Association for Cancer Research Immuno-Oncology (AACR-IO) Conference in Los Angeles. The retrospective analyses demonstrat.
seekingalpha.com
Agenus Inc. (AGEN) Discusses Zydus Collaboration, Global Manufacturing Expansion, and Patient Access Initiatives Transcript
businesswire.com
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #BAL--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the expansion of its global Medical Affairs infrastructure and early-access support capabilities in response to increasing physician-initiated interest regarding authorized access to the investigational immunotherapy combination botensilimab plus balstilimab (BOT+BAL). The expansion reflects increasing interest from treating oncologists worldwide seeking access to BOT+BAL for p.
businesswire.com
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #Access--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in immuno-oncology, today announced it will host its first Stakeholder Webcast of 2026, Access to Acceleration: Agenus' Global Momentum Entering 2026 on Wednesday, January 28, 2026, at 4:00 p.m. ET. The webcast will highlight how expanding global access pathways, strategic partnerships, and operational readiness are driving momentum for Agenus' botensilimab and balstilimab (BOT+BAL) program entering 2026. The ses.
See all news
